PDF(Pubmed)
Abstract：
Gymnema sylvestre (GS) and berberine (BBR) are natural products that have demonstrated therapeutic potential for the management of obesity and its comorbidities, as effective and safe alternatives to synthetic drugs. Although their anti-obesogenic and antidiabetic properties have been widely studied, comparative research on their impact on the gene expression of adipokines, such as resistin (Res), omentin (Ome), visfatin (Vis) and apelin (Ap), has not been reported.
METHODS: We performed a comparative study in 50 adult Mexican patients with obesity treated with GS or BBR for 3 months. The baseline and final biochemical parameters, body composition, blood pressure, gene expression of Res, Ome, Vis, and Ap, and safety parameters were evaluated.
RESULTS: BBR significantly decreased (p < 0.05) body weight, blood pressure and Vis and Ap gene expression and increased Ome, while GS decreased fasting glucose and Res gene expression (p < 0.05). A comparative analysis of the final measurements revealed a lower gene expression of Ap and Vis (p < 0.05) in patients treated with BBR than in those treated with GS. The most frequent adverse effects in both groups were gastrointestinal symptoms, which attenuated during the first month of treatment.
CONCLUSIONS: In patients with obesity, BBR has a better effect on body composition, blood pressure, and the gene expression of adipokines related to metabolic risk, while GS has a better effect on fasting glucose and adipokines related to insulin resistance, with minimal side effects.
METHODS: We performed a comparative study in 50 adult Mexican patients with obesity treated with GS or BBR for 3 months. The baseline and final biochemical parameters, body composition, blood pressure, gene expression of Res, Ome, Vis, and Ap, and safety parameters were evaluated.
RESULTS: BBR significantly decreased (p < 0.05) body weight, blood pressure and Vis and Ap gene expression and increased Ome, while GS decreased fasting glucose and Res gene expression (p < 0.05). A comparative analysis of the final measurements revealed a lower gene expression of Ap and Vis (p < 0.05) in patients treated with BBR than in those treated with GS. The most frequent adverse effects in both groups were gastrointestinal symptoms, which attenuated during the first month of treatment.
CONCLUSIONS: In patients with obesity, BBR has a better effect on body composition, blood pressure, and the gene expression of adipokines related to metabolic risk, while GS has a better effect on fasting glucose and adipokines related to insulin resistance, with minimal side effects.
摘要：
Gymnemasylvestre（GS）和小檗碱（BBR）是天然产物，已证明其治疗肥胖及其合并症的治疗潜力，作为合成药物的有效和安全的替代品。尽管它们的抗肥胖和抗糖尿病特性已被广泛研究，比较研究它们对脂肪因子基因表达的影响，如抵抗素(Res)，门汀(Ome),内脂素（Vis）和Apelin（Ap），尚未报告。
方法：我们在50名墨西哥成年肥胖患者中进行了一项比较研究，患者接受GS或BBR治疗3个月。基线和最终生化参数，身体成分,血压,Res的基因表达，Ome,Vis,还有Ap,并对安全参数进行了评估。
结果：BBR显着降低（p<0.05）体重，血压和Vis和Ap基因表达以及Ome增加，而GS降低空腹血糖和Res基因表达(p<0.05)。最终测量结果的比较分析显示,与用GS治疗的患者相比,用BBR治疗的患者中Ap和Vis的基因表达较低(p<0.05)。两组中最常见的不良反应是胃肠道症状，在治疗的第一个月减弱。
结论：在肥胖患者中，BBR对身体成分有更好的影响，血压,以及与代谢风险相关的脂肪因子的基因表达，而GS对空腹血糖和与胰岛素抵抗相关的脂肪因子有更好的影响，副作用最小。
方法：我们在50名墨西哥成年肥胖患者中进行了一项比较研究，患者接受GS或BBR治疗3个月。基线和最终生化参数，身体成分,血压,Res的基因表达，Ome,Vis,还有Ap,并对安全参数进行了评估。
结果：BBR显着降低（p<0.05）体重，血压和Vis和Ap基因表达以及Ome增加，而GS降低空腹血糖和Res基因表达(p<0.05)。最终测量结果的比较分析显示,与用GS治疗的患者相比,用BBR治疗的患者中Ap和Vis的基因表达较低(p<0.05)。两组中最常见的不良反应是胃肠道症状，在治疗的第一个月减弱。
结论：在肥胖患者中，BBR对身体成分有更好的影响，血压,以及与代谢风险相关的脂肪因子的基因表达，而GS对空腹血糖和与胰岛素抵抗相关的脂肪因子有更好的影响，副作用最小。
